Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, PTC Therapeutics Inc’s stock clocked out at $52.76, down -1.59% from its previous closing price of $53.61. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 0.57 million shares were traded. PTCT stock price reached its highest trading level at $54.65 during the session, while it also had its lowest trading level at $51.925.
Ratios:
To gain a deeper understanding of PTCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.31 and its Current Ratio is at 2.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 11, 2025, Upgraded its rating to Neutral and sets its target price to $55 from $41 previously.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $55.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 13, 2024, whereas the target price for the stock was revised from $45 to $67.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 13 ’25 when Okey Stephanie bought 5,000 shares for $54.00 per share.
Boulding Mark Elliott sold 68,039 shares of PTCT for $3,611,982 on Mar 10 ’25. The EXEC. VP AND CLO now owns 103,901 shares after completing the transaction at $53.09 per share. On Mar 11 ’25, another insider, Boulding Mark Elliott, who serves as the EXEC. VP AND CLO of the company, sold 7,381 shares for $53.02 each. As a result, the insider received 391,323 and left with 103,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 4161149440 and an Enterprise Value of 5478765056. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.16. Its current Enterprise Value per Revenue stands at 6.791 whereas that against EBITDA is -77.075.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.55, which has changed by 0.78544843 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $55.60, while it has fallen to a 52-week low of $24.00. The 50-Day Moving Average of the stock is 9.09%, while the 200-Day Moving Average is calculated to be 30.68%.
Shares Statistics:
It appears that PTCT traded 715.54K shares on average per day over the past three months and 1033790 shares per day over the past ten days. A total of 77.70M shares are outstanding, with a floating share count of 76.80M. Insiders hold about 2.62% of the company’s shares, while institutions hold 97.65% stake in the company. Shares short for PTCT as of 1740700800 were 3789596 with a Short Ratio of 5.30, compared to 1738281600 on 4161584. Therefore, it implies a Short% of Shares Outstanding of 3789596 and a Short% of Float of 7.380000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
